Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
- Study type
- Clinical guideline
- Study name
- ICML Imaging Consensus 2014 (Lugano)
- Design
- Consensus statement of an international working group (review of the literature, exchange of knowledge on ongoing research, and presentation at international workshops and conferences)
- Sample size
- Not applicable (consensus statement)
- Source
- JCO · 2014
In plain words
This document gives the recommendations of international experts on how to use PET-CT scans to find the stage of the disease and measure the response to treatment in lymphoma. Its aim is for doctors around the world to interpret scans more consistently and so guide treatment better. How your scan is interpreted, and what decision is made based on it, should be discussed with your treating doctor.
Key guideline recommendations
- Not stated in the abstract
Recommendations were made to optimise the use of PET-CT in the staging and response assessment of lymphoma, including qualitative and quantitative methods. The exact wording of each recommendation and its level of evidence are not in the abstract and are available in the full text of the paper.
Study population
This document was developed for [18F]fluorodeoxyglucose-avid (FDG-avid) lymphomas in clinical practice and late-phase trials.
Endpoints
This paper is not a trial and has no endpoint. Its aim was to update guidance on the use of PET-CT in the staging and response assessment of FDG-avid lymphomas.
Safety and side effects
No data on adverse events are reported in the abstract.
Clinical significance and place in guidelines
This consensus updates the previous PET guidance (International Harmonization Project) and optimises the use of PET-CT in the staging and response assessment of FDG-avid lymphomas, both in clinical practice and in late-phase trials. The abstract refers to the five-point scale for grading response, which is widely used. The exact adoption of these recommendations in current guidelines should be checked separately.
Limitations
The abstract only outlines the consensus, and the details of the recommendations and the level of evidence are not given. This document was developed for FDG-avid lymphomas.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.